BioSpace News Archive

GE Healthcare will distribute the Nyansa Voyance platform in health care facilities, as the sole distributor, to give health care biomed and IT organizations heightened visibility and control over increasingly complex mobile access infrastructure that is now essential to a world-class patient experience [10-June-2019] CHICAGO and PALO ALTO, Calif. , June 10, 2019 /P

Sigilon Therapeutics announced the addition to its patent portfolio of U.S. Patent Nos. 10,285,949 and 10,292,936, which are entitled “Modified alginates for cell encapsulation and cell therapy.”

With this expansion of the O3 platform, the benefits of monitoring with O3 are now available to patients of all ages, from neonates to adults.

The Company anticipates results of the Phase 3 trial will be announced by the end of 2020.

In a letter sent to former patients and friends, Dr. Joseph P. Galichia, MD, FACC, said, “This past week, the details of a settlement I reached with the Department of Justice after seven years of negotiations were made public.

Following the completion of the Exchange, the Issuer changed its name to “Edesa Biotech, Inc.” and Dr. Nijhawan was appointed as the Chief Executive Officer and Secretary of the Issuer.

These data support using SelectMDx to help guide initial prostate biopsy decisions

Existing Supply Agreement Remains Intact

Three key leaders for OSF Innovation have been selected to present this fall at the American Medical Association’s ChangeMedEd 2019 conference which brings together leaders who are transforming how physicians and residents are trained.

First Commercial Patient Prescribed with the ZOLL µCor Heart Failure and Arrhythmia Management System